drugset / Trial / NCT00468039

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

NCT00468039

Phase 3 Completed 94 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.

Timeline

Start
2007-03-06
Primary completion
2008-06-06
Completion
2008-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg
Subject Vildagliptin Other / unclassified 100 mg